Cognition models and drug discovery

Animal Models of Cognitive Impairment

Volumn , Issue , 2006, Pages 343-353

  Decker, Michael W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057444567     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (38)

1. Decker, M.W., Animal models of cognition, Crit. Rev. Neurobiol., 9, 321, 1995.
2. Müller, U., Mottweiler, E., and Bublak, P., Noradrenergic blockade and numeric working memory in humans, J. Psychopharmacol., 19, 21, 2005.
3. Sayaha, D.M. et al., A genetic screen for novel behavioral mutations in mice, Molecular Psychiatry, 5, 369, 2000.
4. Tecott, L.H. and Nestler, E.J., Neurobehavioral assessment in the information age, Nat. Neurosci., 7, 462, 2004.
5. Crabbe, J.C. and Morris, R.G.M., Festina lente: late-night thoughts on high-throughput screening of mouse behavior, Nat. Neurosci., 7, 1175, 2004.
6. Atkinson-Leadbeater, K., Nuttley, W.M., and van der Kooy, D., A genetic dissociation of learning and recall in Caenorhabditis elegans, Behavioral Neurosci., 118, 1206, 2004.
7. Dubnau, J. and Tully, T., Gene discovery in drosophila: new insights for learning and memory, Ann. Rev. Neurosci., 21, 407, 1998.
8. 2+ signaling via the neuronal calcium sensor-1 regulates associative learning and memory in C. elegans, Neuron, 30, 241, 2001.
9. Sarter, M., Hagan, J., and Dudchenko, P., Behavioral screening for cognition enhancers: from indiscriminate to valid testing: part I, Psychopharmacology, 107, 144, 1992.
10. Sarter, M., Hagan, J., and Dudchenko, P., Behavioral screening for cognition enhancers: from indiscriminate to valid testing: part II, Psychopharmacology, 107, 461, 1992.
11. Robbins, T., The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry, Psychopharmacology, 163, 362, 2002.
12. Wayner, M.J. and Sanberg, P.R., Neural mechanisms of behavior: performance vs. learning, Brain Res. Bull., 23, 331, 1989.
13. McGaugh, J.L., Dissociating learning and performance: drug and hormone enhancement of memory storage, Brain Res. Bull., 23, 339, 1989.
14. Sarter, M. et al., Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection, Brain Res. Rev., 48, 98, 2005.
15. Sarter, M., Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin? Psychopharmacology, 114, 539, 1994.
16. Decker, M.W., Bannon, A.W., and Curzon, P., Septal lesions as model for evaluating potential cognition enhancers, in The Behavioral Neuroscience of the Septal Region, Numan, R., Ed., Springer-Verlag, New York, 2000, p. 363.
17. Matsuoka, N. et al., Differential effects of physostigmine and pilocarpine on the spatial memory deficits produced by two septo-hippocampal deafferentations in rats, Brain Res., 559, 233, 1991.
18. Decker, M. et al., Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics, Life Sci., 56, 545, 1995.
19. Levin, E.D., Nicotinic systems and cognitive function, Psychopharmacology, 108, 417, 1992.
20. Bartus, R.T., On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis, Experimental Neurol., 163, 495, 2000.
21. Bartus, R.T. et al., The cholinergic hypothesis of geriatric memory dysfunction, Science, 217, 408, 1982.
22. Warburton, D.M. and Wesnes, K., Drugs as research tools in psychology: cholinergic drugs and information processing, Neuropsychobiology, 11, 121, 1984.
23. Christensen, H. et al., Cholinergic “blockade” as a model of the cognitive deficits in Alzheimer’s disease, Brain, 115, 1681, 1992.
24. Billings, L.M. et al., Intraneuronal AB causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice, Neuron, 45, 675, 2005.
25. Spowart-Manning, L. and van der Staay, F.J., Spatial discrimination deficits by excitotoxic lesions in the Morris water escape task, Behavioural Brain Res., 156, 269, 2005.
26. Van Dam, D. et al., Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model, Psychopharmacology, 180, 177, 2005.
27. Elia, J., Ambrosini, P.J., and Rapoport, J.L., Treatment of attention-deficit-hyperactivity disorder, N. Engl. J. Med., 340, 780, 1999.
28. Green, M.F. and Nuechterlein, K.H., The MATRICS Initiative: developing a consensus cognitive battery for clinical trials, Schizophrenia Research, 72, 1, 2004.
29. Floresco, S.B. et al., Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia, Schizophrenia Bulletin, 31, 888, 2005.
30. Braff, D.L., Grillon, C., and Geyer, M.A., Gating and habituation of the startle reflex in schizophrenic patients, Arch. Gen. Psychiatry, 49, 206, 1992.
31. Geyer, M.A. et al., Startle response models of sensorimotor gating and habituation deficits in schizophrenia, Brain Res. Bull., 25, 485, 1990.
32. Fortier, C.B. et al., Conditional discrimination learning in patients with bilateral medial temporal lobe amnesia, Behavioral Neurosci., 117, 1181, 2003.
33. Weiss, C. et al., Impaired eyeblink conditioning and decreased hippocampal volume in PDAPP v717f mice, Neurobiol. Dis., 11, 425, 2002.
34. Solomon, P.R. et al., Classical eyeblink conditioning in Alzheimer’s disease patients, Neurobiol. Aging, 12, 283, 1992.
35. Kesner, R.P., Crutcher, K., and Beers, D.R., Serial position curves for item (spatial location) information: role of the dorsal hippocampal formation and medial septum, Brain Res., 454, 219, 1988.
36. Kesner, R.P., Crutcher, K.A., and Measom, M.O., Medial septal and nucleus basalis magnocellularis lesions produce order memory deficits in rats with mimic symptomatology of Alzheimer’s disease, Neurobiol. Aging, 7, 287, 1986.
37. Kesner, R.P. and Ragozzino, M.E., Structure and dynamics of multiple memory systems in Alzheimer’s disease, in Pharmacological Treatment of Alzheimer’s Disease: Molecular and Neurobiological Foundations, Brioni, J.D. and Decker, M.W., Eds., Wiley-Liss, New York, 1997, p. 3.
38. Sarter, M., Bruno, J.P., and Himmelheber, A.M., Cortical acetylcholine and attention: neuropharmacological and cognitive principles directing treatment strategies for cognitive disorders, in Pharmacological Treatment of Alzheimer’s Disease: Molecular and Neurobiological Foundations, Brioni, J.D. and Decker, M.W., Eds., Wiley-Liss, New York, 1997, p. 105.